ArticleClinical pharmacology and therapeutics2016
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.Diabetes care · 2021Pooled it
- A Dose-Aware Model for Revealing Dose-Risk Relationship of Drug-Drug Interaction.CPT: pharmacometrics & systems pharmacology · 2025Article
- Evaluation of Drug-Drug Interactions in Pharmacoepidemiologic Research.Pharmacoepidemiology and drug safety · 2025Review
- Data mining results for reduction of adverse drug-drug interaction events in older adults are clinically applicable.Therapeutic advances in drug safety · 2025Article
- Article
- A substructure-aware graph neural network incorporating relation features for drug-drug interaction prediction.Quantitative biology (Beijing, China) · 2024Article
- Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug-drug Interactions.Clinical pharmacokinetics · 2024Article
- Application of an Innovative Data Mining Approach Towards Safe Polypharmacy Practice in Older Adults.Drug safety · 2024Article
- Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study.Frontiers in medicine · 2022Article
- Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study.British journal of clinical pharmacology · 2021Article
- Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.Diabetes care · 2018Article
- Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.Pharmacoepidemiology and drug safety · 2018Article
- Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.Trends in endocrinology and metabolism: TEM · 2017Review
- Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.Epidemiology (Cambridge, Mass.) · 2017Article
- Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.Clinical pharmacology and therapeutics · 2016Review
- Severe Hypoglycemia Associated with Tiapride in an Elderly Patient with Diabetes and Psychosis.Innovations in clinical neuroscienceArticle
- Hyperglycaemia induced by isoniazid preventive therapy.Journal of family medicine and primary careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Drug-drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea use with a statin or fibrate was associated with severe hypoglycemia. We conducted cohort studies of users of glyburide, glipizide, and glimepiride plus a statin or fibrate within a Medicaid population. The outcome was a validated, diagnosis-based algorithm for severe hypoglycemia. Among 592,872 persons newly exposed to a sulfonylurea+antihyperlipidemic, the incidence of severe hypoglycemia was 5.8/100 person-years. Adjusted hazard ratios (HRs) for sulfonylurea+statins were consistent with no association. Most overall HRs for sulfonylurea+fibrate were elevated, with sulfonylurea-specific adjusted HRs as large as 1.50 (95% confidence interval (CI): 1.24-1.81) for glyburide+gemfibrozil, 1.37 (95% CI: 1.11-1.69) for glipizide+gemfibrozil, and 1.63 (95% CI: 1.29-2.06) for glimepiride+fenofibrate. Concomitant therapy with a sulfonylurea and fibrate is associated with an often delayed increased rate of severe hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.